Ignite Creation Date:
2025-12-26 @ 2:41 PM
Ignite Modification Date:
2025-12-26 @ 2:41 PM
Study NCT ID:
NCT06187506
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2023-12-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Sponsor:
Fudan University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-18
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-12-13
First Submit QC Date:
None
Study First Post Date:
2024-01-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-11
Last Update Post Date:
2024-07-12
Last Update Post Date Type:
ACTUAL